Natural Product (NP) Details

General Information of the NP (ID: NP0419)
Name
Triamcinolone
Synonyms
triamcinolone; 124-94-7; Fluoxyprednisolone; Aristocort; Rodinolone; Triamcinolon; Kenacort; Volon; Adcortyl; Delphicort; Ledercort; Triamcet; Tricortale; Celeste; Triam-Tablinen; Cinolone-T; SK-Triamcinolone; Triamcinlon; Fluoxiprednisolone; Triamcinolonum [INN]; Triamcinalone; Triamcinolona; Triamcinolonum; Tiamcinolonum [INN-Latin]; Triamcinolona [INN-Spanish]; Kenacort-AG; 9alpha-Fluoro-16alpha-hydroxyprednisolone; CL 19823; Mycolog; UNII-1ZK20VI6TY; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Omcilon; 1ZK20VI6TY; Aristocort Tablets; MLS000028542; MLS001066543; CHEBI:9667; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; 124-94-7 (free); 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; NSC13397; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; NSC-13397; Tiamcinolonum; SMR000058333; Prednisolone, 9-fluoro-16.alpha.-hydroxy-; NSC 13397; DSSTox_CID_20742; DSSTox_RID_79584; DSSTox_GSID_40742; 11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione; Kenacort (TN); 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Triamcinolone (Aristocort); HSDB 3194; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; EINECS 204-718-7; BRN 2341955; Prednisolone, 9-fluoro-16alpha-hydroxy-; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)-; NCGC00094799-01; CAS-124-94-7; Triamcinolone [USP:INN:BAN:JAN]; Prestwick_438; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; Triamcinolone, topical; Prestwick0_000120; Prestwick1_000120; Prestwick2_000120; Prestwick3_000120; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-; SCHEMBL4447; CHEMBL1451; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11-beta,16-alpha)-; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)-; Lopac0_001179; BSPBio_000140; 4-08-00-03629 (Beilstein Handbook Reference); cid_31307; MLS002695935; SPBio_002079; BPBio1_000154; GTPL2870; DTXSID1040742; BDBM41132; Triamcinolone (JP17/USP/INN); HMS1568G22; HMS2090D12; HMS2095G22; HMS2231E20; HMS3263L19; HMS3712G22; BCP11941; EX-A4109; HY-B0328; ZINC3882036; Tox21_111332; Tox21_300178; Tox21_501179; MFCD00010477; s1933; AKOS015895436; Tox21_111332_1; AC-2072; CCG-205253; DB00620; LP01179; SDCCGSBI-0051146.P002; (11beta,16alpha)-9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 11.beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; BRN-2341955; SMP1_000300; NCGC00021580-03; NCGC00021580-04; NCGC00021580-05; NCGC00021580-06; NCGC00021580-07; NCGC00021580-08; NCGC00021580-16; NCGC00178404-03; NCGC00254049-01; NCGC00261864-01; 51855-44-8; AS-13657; NCI60_000750; EU-0101179; D00385; J10062; 124T947; SR-01000000079; Q1074056; SR-01000000079-3; BRD-K77554836-001-03-3; BRD-K77554836-001-14-0; Triamcinolone, British Pharmacopoeia (BP) Reference Standard; Triamcinolone, European Pharmacopoeia (EP) Reference Standard; WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ; Triamcinolone, United States Pharmacopeia (USP) Reference Standard; 3-[2[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]ETHYL]-PIPERIDINE; 9.alpha.-Fluoro-11.beta.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; Pregna-1,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; 11.beta.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; Pregna-1,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11.beta.,16.alpha.)-; Pregna-1,4-diene-3, 20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI); (1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)-, tetrahydro deriv.
    Click to Show/Hide
Species Origin Cladosporium ...     Click to Show/Hide
Cladosporium
Kingdom: Fungi
Phylum: Ascomycota
Class: Dothideomycetes
Order: Cladosporiales
Family: Cladosporiaceae
Genus: Cladosporium
Disease Vasomotor/allergic rhinitis [ICD-11: CA08] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -4.826
 
MDCK Permeability
 -4.703
 
PAMPA
 +++
 
HIA
 - - -
 
Distribution
VDss
 0.298
 
PPB
 83.1%
 
BBB
 -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 - - -
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 +
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 +++
HLM Stability
 - - -
 
Excretion
CLplasma
 2.843
 
T1/2
 2.374
Toxicity
DILI
 - - -
 
Rat Oral Acute Toxicity
 ++
 
FDAMDD
 +++
 
Respiratory
 +++
 
Human Hepatotoxicity
 +
 
Ototoxicity
 ++
 
Drug-induced Nephrotoxicity
 +
 
Drug-induced Neurotoxicity
 - - -
 
Hematotoxicity
 - - -
 
Genotoxicity
 +++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C21H27FO6
PubChem CID
31307
Canonical SMILES
CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O
InChI
1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
InChIKey
GFNANZIMVAIWHM-OBYCQNJPSA-N
CAS Number
CAS 124-94-7
ChEBI ID
CHEBI:9667
TTD Drug ID
D03BLF
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          5-fluorouracil      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression COL1A1  Molecule Info 
Pathway MAP
Down-regulation Expression TGFB1  Molecule Info 
Pathway MAP
                    Biological
                    Regulation		 Induction Cell cycle arrest in G2 phase
                    In-vitro Model Keloid fibroblasts Healthy Homo sapiens
                    Experimental
                    Result(s)		 Combination of TA and 5-FU showed synergistic interation in regulating the biological behaviour of keloid fibroblasts in vitro.
          Bevacizumab      Colorectal cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model A case report
                    Experimental
                    Result(s)		 Combination in close sequence resulted in a dramatic improvement in vision and cystoid macular edema.
Target and Pathway
Target(s) Glucocorticoid receptor (NR3C1)  Molecule Info  [4]
KEGG Pathway Neuroactive ligand-receptor interaction Click to Show/Hide
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
2 TCR Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling Click to Show/Hide
2 Signaling events mediated by HDAC Class II
3 FOXA2 and FOXA3 transcription factor networks
4 Glucocorticoid receptor regulatory network
5 Regulation of Androgen receptor activity
6 AP-1 transcription factor network
Reactome BMAL1:CLOCK,NPAS2 activates circadian gene expression Click to Show/Hide
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling Click to Show/Hide
2 SIDS Susceptibility Pathways
3 Nuclear Receptors Meta-Pathway
4 Endoderm Differentiation
5 Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
6 Adipogenesis
7 Circadian Clock
8 Nuclear Receptors
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblasts in vitro. J Plast Reconstr Aesthet Surg. 2013 Sep;66(9):e251-9.
Reference 3 Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone. Eye (Lond). 2007 Aug;21(8):1128-30.
Reference 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link